Kubera Health | $6,500,000 | (May 29, 2026)
Crimson | $2,500,000 | (May 29, 2026)
Volt Harbor Inc. | $2,000,000 | (May 29, 2026)
Certified by Founder
Lodge
NeuroSense Therapeutics
start up
United States
- Cambridge, Massachusetts
- 09/12/2021
- Unknown
- $12,000,000
Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in preparations towards a Phase IIb in ALS patients in USA and Israel.
- Industry Biotechnology Research
- Website http://www.neurosense-tx.com/
- LinkedIn https://www.linkedin.com/company/neurosense-therapeutics/about/
Related People
Alon Ben-NoonCo Founder
Israel -
Herzliyya, Tel Aviv
Life Sciences Executive ; Leading NeuroSense Therapeutics, a Biotech startup which accelerates research, development and therapy for ALS (Amyotrophic Lateral Sclerosis) and additional Neurodegenerative diseases.
LinkedIn
https://www.linkedin.com/in/alonbn/
Countable Labs | $26,000,000 | (May 29, 2026)
Solstice | $21,000,000 | (May 29, 2026)
Rep AI | $6,200,000 | (May 29, 2026)
Psilera | $8,800,000 | (May 29, 2026)
Reactor | $59,000,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)
Blulabs | $7,000,000 | (May 29, 2026)
allO | $14,000,000 | (May 29, 2026)